Physician profile
Ravi Passi
NPI 1114921665
$5,027.02
in general payments reported to CMS, 2019-2025
49 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $540 · 2021: $751 · 2022: $665 · 2023: $1,073 · 2024: $797 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $36.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.79 |
| Education | $36.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $601.66 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $382.33 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.63 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $369.41 | 2020-2025 | Evenity, Prolia, Uplizna |
| Lilly USA, LLC | $321.09 | 2019-2025 | Kisunla, Trulicity, Basaglar |
| Novartis Pharmaceuticals Corporation | $309.30 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $255.83 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Acadia Pharmaceuticals INC | $252.47 | 2020-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $250.12 | 2019-2022 | |
| Ucb, INC. | $188.48 | 2019-2024 | Nayzilam |
| Lundbeck LLC | $137.06 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $119.68 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $118.80 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $111.49 | 2019-2024 | |
| Glaxosmithkline, LLC. | $108.05 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 46 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Passi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.